Biorestorative Therapies (NASDAQ:BRTX) Shares Scheduled to Reverse Split on Tuesday, September 8th

Biorestorative Therapies, Inc. (NASDAQ:BRTX)’s stock is set to reverse split before the market opens on Tuesday, September 8th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, September 7th.

Biorestorative Therapies Stock Performance

Shares of Biorestorative Therapies stock opened at $0.14 on Friday. The business’s 50 day moving average price is $0.27 and its 200 day moving average price is $0.28. The company has a market cap of $3.66 million, a price-to-earnings ratio of -0.13 and a beta of 0.83. Biorestorative Therapies has a one year low of $0.14 and a one year high of $1.73.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday, August 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Biorestorative Therapies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BRTX. DRW Securities LLC acquired a new position in shares of Biorestorative Therapies in the 4th quarter valued at $55,000. Citadel Advisors LLC acquired a new position in Biorestorative Therapies in the third quarter valued at about $152,000. Finally, Virtu Financial LLC lifted its position in Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after buying an additional 12,319 shares during the last quarter. Hedge funds and other institutional investors own 69.38% of the company’s stock.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.